• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$3.82 -$0.02 (-0.52%)

REAL-TIME: Last trade at

Oncolytics Biotech, Inc. (USA)

NASDAQ:ONCY

Jump to this page for:

Related Resources

Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch 2012 Heath Care Conference

5/15/2012 by PR Newswire

Oncolytics Biotech loses $8.45-million in Q1 2012

5/10/2012 by StockWatch

Oncolytics Biotech® Inc. Announces First Quarter 2012 Results

5/10/2012 by PR Newswire

Oncolytics Biotech enters sponsorship agreement with NCIC CTG

5/3/2012 by Theflyonthewall.com

Oncolytics Biotech® Inc. Completes Enrollment In First Stage Of Phase III Study In Head And Neck Cancers

4/4/2012 by Biocompare

Media Advisory - Oncolytics Biotech® Inc. to Present at 11th Annual Needham Healthcare Conference

4/4/2012 by PR Newswire

Oncolytics Biotech (ONCY) Completes Enrollment in REOLYSIN w/ Aclitaxel and Carboplatin Phase III

4/2/2012 by StreetInsider.com

Oncolytics Biotech® Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers

4/2/2012 by PR Newswire

Oncolytics Biotech® Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting

3/29/2012 by PR Newswire

Oncolytics Biotech loses $29.04-million in 2011

3/15/2012 by StockWatch

Oncolytics Biotech® Inc. Announces 2011 Year End Results

3/15/2012 by PR Newswire

Media Advisory - Oncolytics Biotech® Inc. to Present at Cowen and Company 32nd Annual Health Care Conference

3/2/2012 by PR Newswire

Oncolytics Biotech enters into sponsorship agreement with NCIC CTG

2/21/2012 by Theflyonthewall.com

Oncolytics Biotech® Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer

2/21/2012 by PR Newswire

Oncolytics Biotech® Inc. Closes Bought Deal Financing for Total Gross Proceeds of Cdn$21.3 Million

2/8/2012 by StockWatch

8 Stocks Under $10 Moving Higher

2/2/2012 by TheStreet.com

Oncolytics Biotech rises 28.5%

1/30/2012 by Theflyonthewall.com

Oncolytics Biotech rises 26.8%

1/30/2012 by Theflyonthewall.com

Oncolytics Biotech Inc. Announces C$15 Million Bought Deal Financing

1/24/2012 by BioSpace

Oncolytics Biotech (ONCY) Announcs Offering of 3.57M Shares for Cdn$4.20/Share

1/23/2012 by StreetInsider.com

Oncolytics Biotech Inc. Announces Phase 2 Clinical Trial of REOLYSIN in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint

12/2/2011 by Genetic Engineering News

Oncolytics Biotech: Phase 2 clinical trial of REOLYSIN with Gemcitabine

12/2/2011 by Theflyonthewall.com

Oncolytics Biotech® Inc. Announces Phase 2 Clinical Trial of REOLYSIN® in Combination with Gemcitabine in Pancreatic Cancer Reaches Primary Endpoint

12/2/2011 by PR Newswire

Oncolytics Biotech Inc. Announces Start of Conformity Testing with SAFC

11/21/2011 by Genetic Engineering News

Oncolytics Biotech announces start of conformity testing with SAFC

11/21/2011 by Theflyonthewall.com

Oncolytics Biotech® Inc. Announces Start of Conformity Testing with SAFC®

11/21/2011 by PR Newswire

Oncolytics Biotech Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers

11/14/2011 by Genetic Engineering News

Oncolytics: positive results of U.S. Phase 2 REOLYSIN trial with Paclitaxel

11/14/2011 by Theflyonthewall.com

Oncolytics Biotech® Inc. Announces Positive Results of U.S. Phase 2 Clinical Trial Investigating REOLYSIN® in Combination with Paclitaxel and Carboplatin in Head and Neck Cancers

11/14/2011 by PR Newswire

Oncolytics Biotech Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

11/11/2011 by Genetic Engineering News

Oncolytics Biotech® Inc. to Host Conference Call to Discuss Clinical Data Being Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

11/11/2011 by PR Newswire

Oncolytics Biotech® Inc. Announces Third Quarter 2011 Results

11/10/2011 by StockHouse

Oncolytics Biotech Announces Appointments to Senior Management Team

11/10/2011 by Genetic Engineering News

Oncolytics Biotech reports Q3 EPS (9c) vs. consensus (11c)

11/10/2011 by Theflyonthewall.com

Oncolytics Biotech® Inc. Announces Third Quarter 2011 Results

11/10/2011 by PR Newswire

Oncolytics Biotech Announces Appointments to Senior Management Team

11/10/2011 by PR Newswire

Wall Street's Buy List

10/10/2011 by The Motley Fool

Media Advisory - Oncolytics Biotech® Inc. to Present at the JMP Securities Healthcare Conference

9/22/2011 by StockWatch

Media Advisory - Oncolytics Biotech® Inc. to Present at the JMP Securities Healthcare Conference

9/22/2011 by PR Newswire

Oncolytics Biotech management to meet with RBC Capital

9/12/2011 by Theflyonthewall.com
See More Articles...